TNF‐α‐induced cardiomyocyte apoptosis contributes to cardiac dysfunction after coronary microembolization in mini‐pigs
Key result
Pre-treatment with adalimumab significantly improved left ventricular ejection fraction at 1 week after coronary microembolization (56.7% vs 52.7%, P=0.041) and suppressed cardiomyocyte apoptosis.
Why the study?
Does adalimumab pre-treatment improve cardiac function and reduce cardiomyocyte apoptosis after coronary microembolization in mini-pigs?
Population
19 mini-pigs undergoing coronary microembolization (CME)
Comparison
Adalimumab 2 mg/kg intracoronary injection… vs CME without adalimumab pre-treatment, and…
Design
Preclinical
Follow-up
1 week
Authors
Discussion
Loading...
Member takes
Implication
Adalimumab pre-treatment warrants no clinical adoption; hypothesis-generating for TNF-α inhibition in coronary microembolization.
Structured PICO
Does adalimumab pre-treatment improve cardiac function and reduce cardiomyocyte apoptosis after coronary microembolization in mini-pigs?
P
Population
19 mini-pigs undergoing coronary microembolization (CME)
I
Intervention
Adalimumab (TNF-α antibody) 2 mg/kg intracoronary injection before CME
C
Comparator
CME without adalimumab pre-treatment, and sham-operation
O
Outcome
Left ventricular ejection fraction (LVEF) and cardiomyocyte apoptosis at 6 hours and 1 weeksurrogate
Main Result
Absolute Event Rate: 56.7% vs 52.7%
p-value: p=0.041
TNF-α antibody therapy with adalimumab suppresses cardiomyocyte apoptosis and improves early cardiac function after coronary microembolization in a mini-pig model.
Cite This Study
Chen et al. (2014) studied coronary microembolization (n=19). adalimumab vs. coronary microembolization without adalimumab was evaluated on Left ventricular ejection fraction (LVEF) at 1 week (p=0.041). Pre-treatment with adalimumab significantly improved left ventricular ejection fraction at 1 week after coronary microembolization (56.7% vs 52.7%, P=0.041) and suppressed cardiomyocyte apoptosis.